Opsis Therapeutics announces SAB for advancement in retinal cell therapies
Opsis Therapeutics announced that their executive leadership team has approved its scientific advisory board (SAB) responsible to advise on the development and advancement to the first-in-class retinal cell therapies.
The inaugural members of the Opsis SAB are:
- Kapil Bharti, Ph.D. – Stadtman Investigator, Unit on Ocular Stem Cell & Translational Research, National Eye Institute (NEI), US National Institutes of Health (NIH);
- Eric A. Pierce, M.D., Ph.D. – Director, Inherited Retinal Disorders Service; Director, Berman-Gund Laboratory for the Study of Retinal Degenerations; Director, Ocular Genomics Institute at Massachusetts Eye and Ear; Solman and Libe Friedman Associate Professor of Ophthalmology at Harvard Medical School;
- Paul A. Sieving, M.D., Ph.D. – Senior Investigator, National Institutes of Health, Intramural Research Program, Laboratory of Translational Research on Retinal and Macular Degenerations. Member, National Academy of Medicine, USA.
- James A. Thomson, Ph.D., DVM – Director of Regenerative Biology, Morgridge Institute for Research; John D. MacArthur Professor of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health; Professor of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara; Member, National Academy of Sciences (NAS); Co-Founder of Cellular Dynamics International (CDI), a FUJIFILM company
Opsis Co-Founder and CSO, David Gamm said that they are thrilled to have such talented and experienced scientific advisors providing critical expertise to their team. Their SAB, composed of renowned experts in retinal disease, is aimed at guiding the company in its scientific and development efforts to advance their cell-based therapies to the clinic. They are delighted to benefit from such invaluable input as they develop their therapeutic pipeline.